Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes

References

• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–1619.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058.e3.
   PubMed Web of Science ®Google Scholar
• Daperno M, Castiglione F, de Ridder L, et al. Results of the 2nd part scientific workshop of the ECCO. II: measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis. 2011;5(5):484–498.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5(5):477–483.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883.
   PubMed Web of Science ®Google Scholar
• Falvey JD, Hoskin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21(4):824–831.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17(4):1008–1014.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterology. 2007;102(4):794–802.
   PubMed Web of Science ®Google Scholar
• Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019;14(2):e0212989.
   PubMed Web of Science ®Google Scholar
• Ryan C, Sobell JM, Leonardi CL, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19(3):437–447.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95.
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis [NCT02435992]. [cited 2022 May 3]. Available at: https://clinicaltrials.gov/ct2/show/NCT02435992?term=ozanimod&type=Intr&cond=Ulcerative+Colitis&intr=Ozanimod&phase=2&draw=2&rank=2.
   Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–786.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(9):1245–1255.e8.
   PubMed Web of Science ®Google Scholar
• Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(11):2510–2517.e5.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Burger DC, Delo J, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65(3):408–414.
   PubMed Web of Science ®Google Scholar
• Mazzuoli S, Guglielmi FW, Antonelli E, et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45(12):969–977.
   Google Scholar
• Boal Carvalho P, Cotter J. Mucosal healing in ulcerative colitis: a comprehensive review. Drugs. 2017;77(2):159–173.
   PubMed Web of Science ®Google Scholar
• Aniwan S, Bruining DH, Park SH, et al. The combination of patient-reported clinical symptoms and an endoscopic score correlates well with health-related quality of life in patients with ulcerative colitis. J Clin Med. 2019;8(8):1171.
   PubMed Web of Science ®Google Scholar
• Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis. 2016;10(1):13–19.
   PubMed Web of Science ®Google Scholar
• Boal Carvalho P, Dias de Castro F, Rosa B, et al. Mucosal healing in ulcerative colitis—when zero is better. J Crohns Colitis. 2016;10(1):20–25.
   PubMed Web of Science ®Google Scholar
• Cushing KC, Tan W, Alpers DH, et al. Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Aliment Pharmacol Ther. 2020;51(3):347–355.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Naganuma M, Sugimoto S, et al. Efficacy of therapeutic intervention for patients with an ulcerative colitis Mayo endoscopic score of 1. Inflamm Bowel Dis. 2019;25(4):782–788.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Takahashi F, Tominaga K, et al. Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. Endosc Int Open. 2019;7(4):E568–E575.
   PubMed Web of Science ®Google Scholar
• Kim JH, Cheon JH, Park Y, et al. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol. 2016;51(9):1069–1074.
   PubMed Web of Science ®Google Scholar
• Laharie D, Filippi J, Roblin X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther. 2013;37(10):998–1004.
   PubMed Web of Science ®Google Scholar
• Leung CM, Tang W, Kyaw M, et al. Endoscopic and histological mucosal healing in ulcerative colitis in the first year of diagnosis: results from a population-based inception cohort from six countries in Asia. J Crohns Colitis. 2017;11(12):1440–1448.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Bessissow T, Ruiz-Cerulla A, et al. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: a prospective multicenter study. United European Gastroenterol J. 2018;6(5):765–772.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Scott FI, Fogt FF, et al. Endoscopic and histological assessment, correlation, and relapse in clinically quiescent ulcerative colitis (MARQUEE). Inflamm Bowel Dis. 2021;27(2):207–214.
   PubMed Web of Science ®Google Scholar
• Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohns Colitis. 2018;12(11):1288–1294.
   PubMed Web of Science ®Google Scholar
• Ramos L, De La Barreda R, Carrillo-Palau M, et al. Risk of relapse according to endoscopic score of mucosal healing (Mayo score 0 vs 1): clinical evaluation is still necessary [abstract P256]. J Crohns Colitis. 2018;12(supplement_1):S229–S230.
   Google Scholar
• Muñoz Villafranca C, Rodríguez MTB, de Zárate JO, et al. Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission. Gastroenterol Hepatol. 2016;39(7):442–448.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shimoyama T, Umegae S. Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics. Presented at the 12th Congress of ECCO-Inflammatory Bowel Diseases 2017. Barcelona, Spain.
   Google Scholar
• Yamamoto T, Shimoyama T, Umegae S, et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Transl Gastroenterol. 2018;9(3):136.
   PubMed Web of Science ®Google Scholar
• Kevans D, Kirsch R, Dargavel C, et al. Histological markers of clinical relapse in endoscopically quiescent ulcerative colitis. Inflamm Bowel Dis. 2020;26(11):1722–1729.
   PubMed Web of Science ®Google Scholar
• Nakarai A, Kato J, Hiraoka S, et al. An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing. Gut Liver. 2018;12(4):420–425.
   PubMed Web of Science ®Google Scholar
• Yokoyama K, Kobayashi K, Mukae M, et al. Clinical study of the relation between mucosal healing and long-term outcomes in ulcerative colitis. Gastroenterol Res Pract. 2013;2013:192794.
   PubMed Web of Science ®Google Scholar
• Frieri G, Galletti B, Di Ruscio M, et al. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. Therap Adv Gastroenterol. 2017;10(10):749–759.
   PubMed Web of Science ®Google Scholar
• Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, et al. The impact of endoscopic inflammation and mucosal healing on health-related quality of life in ulcerative colitis patients. J Crohns Colitis. 2015;9(8):625–632.
   PubMed Web of Science ®Google Scholar
• Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107(11):1684–1692.
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(6):483–489.e3.
   PubMed Web of Science ®Google Scholar
• Naganuma M, Hirai F, Kobayashi K, et al. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. PLoS One. 2019;14(8):e0220413.
   Google Scholar
• Zenlea T, Yee EU, Rosenberg L, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol. 2016;111(5):685–690.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut. 2017;66(1):50–58.
   PubMed Web of Science ®Google Scholar
• Stark RG, Reitmeir P, Leidl R, et al. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis. 2010;16(1):42–51.
   PubMed Web of Science ®Google Scholar
• Travis S, Feagan BG, Peyrin-Biroulet L, et al. Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA. J Crohns Colitis. 2017;11(11):1317–1325.
   PubMed Web of Science ®Google Scholar